SparX Biopharmaceutical announces research agreement with Mitsubishi Tanabe Pharma America to advance novel antibody-drug conjugates

CAR-T Digest - August 2020

15 May 2025: SparX Biopharmaceutical announces research agreement with Mitsubishi Tanabe Pharma America to advance novel antibody-drug conjugates

SparX Biopharmaceutical has entered a research agreement with Mitsubishi Tanabe Pharma America to advance a novel antibody-drug conjugate (ADC) program
The collaboration will focus on developing an ADC targeting a first-in-class immune cell target, representing a potential universal tumor-targeting strategy across various cancer types
This research initiative leverages SparX’s next-generation ADC technologies and innovative target discovery platform
The ADC program under development aims to deliver transformative cancer therapies with broad applicability and high precision
The partnership underscores a shared commitment to advancing cutting-edge oncology treatments through strategic collaboration